Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors
Introduction The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown. Methods Primary, incident cases of early stage prostate cancer ( n = 47...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer survivorship 2009-12, Vol.3 (4), p.233-240 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 4 |
| container_start_page | 233 |
| container_title | Journal of cancer survivorship |
| container_volume | 3 |
| creator | Beehler, Gregory P. Wade, Michael Kim, Borah Steinbrenner, Lynn Wray, Laura O. |
| description | Introduction
The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown.
Methods
Primary, incident cases of early stage prostate cancer (
n
= 473) were identified from the Buffalo VA Medical Center tumor registry and matched to body size, demographic, comorbidity, and treatment exposure data from veteran medical records. Multilevel modeling was used to assess the association between ADT and changes in BMI.
Results
On average, survivors were overweight at diagnosis and showed small, non-significant changes in BMI over time. However, among those survivors with a history of ADT, a significant decrease of 0.05 BMI units per year was associated with each additional dose of ADT (
p
|
| doi_str_mv | 10.1007/s11764-009-0099-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_89190876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1897946901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-fbb8b6f20ddd0011f502191744766c24ec8f51833df2c42492f1aa92a62bcd353</originalsourceid><addsrcrecordid>eNp1UMtOwzAQtBCIlsIHcEHmAwJeJ3Gyx1JelYq4lHPkOHaVKo9iO5X697hKBScOq11pZ2Znh5BbYA_AWPboADKRRIzhsTDCMzIFjHnEucjOf-cUJ-TKuS1jKUfgl2QCmAkGCU6JXPXdpvZDVXeyodI57VyrO097Q58-lrTuqNWN9HXfUd_T-fOaDk5T2QYa1dI2B-q83Gi6s30YvKZKdkpb6ga7r_e9ddfkwsjG6ZtTn5Gv15f14j1afb4tF_NVpGKBPjJlmZfCcFZVFWMAJmUcELIkyYRQPNEqNynkcVwZrhKeIDcgJXIpeKmqOI1n5H7UDU6-B-18se0HG75yRY6ALM9EwMCIUcGts9oUO1u30h4KYMUx0mKMtAhxHgsLDJy7k-5Qtrr6Y5wyDAA-AlxYdRtt_w7_r_oDqxqBeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>89190876</pqid></control><display><type>article</type><title>Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Beehler, Gregory P. ; Wade, Michael ; Kim, Borah ; Steinbrenner, Lynn ; Wray, Laura O.</creator><creatorcontrib>Beehler, Gregory P. ; Wade, Michael ; Kim, Borah ; Steinbrenner, Lynn ; Wray, Laura O.</creatorcontrib><description>Introduction
The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown.
Methods
Primary, incident cases of early stage prostate cancer (
n
= 473) were identified from the Buffalo VA Medical Center tumor registry and matched to body size, demographic, comorbidity, and treatment exposure data from veteran medical records. Multilevel modeling was used to assess the association between ADT and changes in BMI.
Results
On average, survivors were overweight at diagnosis and showed small, non-significant changes in BMI over time. However, among those survivors with a history of ADT, a significant decrease of 0.05 BMI units per year was associated with each additional dose of ADT (
p
< 0.001). When the association between BMI rate of change and ADT was allowed to vary with respect to age, additional doses of ADT predicted stronger decreases in BMI for younger survivors as compared to older survivors (
p
< 0.05). Neither a history of surgery nor radiation influenced the association between ADT use and BMI.
Conclusions
Declines in BMI in relation to ADT exposure may be reflective of unfavorable changes in body composition, especially decreased muscle mass, that is most pronounced in younger survivors.
Implications for Cancer Survivors
Survivors on ADT may benefit from close monitoring of physical functioning and referral for exercise interventions to preserve muscle mass and improve health related quality of life.</description><identifier>ISSN: 1932-2259</identifier><identifier>EISSN: 1932-2267</identifier><identifier>DOI: 10.1007/s11764-009-0099-9</identifier><identifier>PMID: 19760149</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Aged ; Androgen Antagonists - therapeutic use ; Androgens ; Body Mass Index ; Drug therapy ; Health Informatics ; Health Promotion and Disease Prevention ; Humans ; Longitudinal Studies ; Male ; Medicine ; Medicine & Public Health ; Oncology ; Primary Care Medicine ; Prognosis ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; Public Health ; Quality of Life Research ; Survivor ; Survivors ; Treatment Outcome</subject><ispartof>Journal of cancer survivorship, 2009-12, Vol.3 (4), p.233-240</ispartof><rights>Springer Science+Business Media, LLC 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-fbb8b6f20ddd0011f502191744766c24ec8f51833df2c42492f1aa92a62bcd353</citedby><cites>FETCH-LOGICAL-c369t-fbb8b6f20ddd0011f502191744766c24ec8f51833df2c42492f1aa92a62bcd353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11764-009-0099-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11764-009-0099-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19760149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beehler, Gregory P.</creatorcontrib><creatorcontrib>Wade, Michael</creatorcontrib><creatorcontrib>Kim, Borah</creatorcontrib><creatorcontrib>Steinbrenner, Lynn</creatorcontrib><creatorcontrib>Wray, Laura O.</creatorcontrib><title>Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors</title><title>Journal of cancer survivorship</title><addtitle>J Cancer Surviv</addtitle><addtitle>J Cancer Surviv</addtitle><description>Introduction
The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown.
Methods
Primary, incident cases of early stage prostate cancer (
n
= 473) were identified from the Buffalo VA Medical Center tumor registry and matched to body size, demographic, comorbidity, and treatment exposure data from veteran medical records. Multilevel modeling was used to assess the association between ADT and changes in BMI.
Results
On average, survivors were overweight at diagnosis and showed small, non-significant changes in BMI over time. However, among those survivors with a history of ADT, a significant decrease of 0.05 BMI units per year was associated with each additional dose of ADT (
p
< 0.001). When the association between BMI rate of change and ADT was allowed to vary with respect to age, additional doses of ADT predicted stronger decreases in BMI for younger survivors as compared to older survivors (
p
< 0.05). Neither a history of surgery nor radiation influenced the association between ADT use and BMI.
Conclusions
Declines in BMI in relation to ADT exposure may be reflective of unfavorable changes in body composition, especially decreased muscle mass, that is most pronounced in younger survivors.
Implications for Cancer Survivors
Survivors on ADT may benefit from close monitoring of physical functioning and referral for exercise interventions to preserve muscle mass and improve health related quality of life.</description><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Androgens</subject><subject>Body Mass Index</subject><subject>Drug therapy</subject><subject>Health Informatics</subject><subject>Health Promotion and Disease Prevention</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Primary Care Medicine</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Public Health</subject><subject>Quality of Life Research</subject><subject>Survivor</subject><subject>Survivors</subject><subject>Treatment Outcome</subject><issn>1932-2259</issn><issn>1932-2267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1UMtOwzAQtBCIlsIHcEHmAwJeJ3Gyx1JelYq4lHPkOHaVKo9iO5X697hKBScOq11pZ2Znh5BbYA_AWPboADKRRIzhsTDCMzIFjHnEucjOf-cUJ-TKuS1jKUfgl2QCmAkGCU6JXPXdpvZDVXeyodI57VyrO097Q58-lrTuqNWN9HXfUd_T-fOaDk5T2QYa1dI2B-q83Gi6s30YvKZKdkpb6ga7r_e9ddfkwsjG6ZtTn5Gv15f14j1afb4tF_NVpGKBPjJlmZfCcFZVFWMAJmUcELIkyYRQPNEqNynkcVwZrhKeIDcgJXIpeKmqOI1n5H7UDU6-B-18se0HG75yRY6ALM9EwMCIUcGts9oUO1u30h4KYMUx0mKMtAhxHgsLDJy7k-5Qtrr6Y5wyDAA-AlxYdRtt_w7_r_oDqxqBeg</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Beehler, Gregory P.</creator><creator>Wade, Michael</creator><creator>Kim, Borah</creator><creator>Steinbrenner, Lynn</creator><creator>Wray, Laura O.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20091201</creationdate><title>Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors</title><author>Beehler, Gregory P. ; Wade, Michael ; Kim, Borah ; Steinbrenner, Lynn ; Wray, Laura O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-fbb8b6f20ddd0011f502191744766c24ec8f51833df2c42492f1aa92a62bcd353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Androgens</topic><topic>Body Mass Index</topic><topic>Drug therapy</topic><topic>Health Informatics</topic><topic>Health Promotion and Disease Prevention</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Primary Care Medicine</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Public Health</topic><topic>Quality of Life Research</topic><topic>Survivor</topic><topic>Survivors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beehler, Gregory P.</creatorcontrib><creatorcontrib>Wade, Michael</creatorcontrib><creatorcontrib>Kim, Borah</creatorcontrib><creatorcontrib>Steinbrenner, Lynn</creatorcontrib><creatorcontrib>Wray, Laura O.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer survivorship</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beehler, Gregory P.</au><au>Wade, Michael</au><au>Kim, Borah</au><au>Steinbrenner, Lynn</au><au>Wray, Laura O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors</atitle><jtitle>Journal of cancer survivorship</jtitle><stitle>J Cancer Surviv</stitle><addtitle>J Cancer Surviv</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>3</volume><issue>4</issue><spage>233</spage><epage>240</epage><pages>233-240</pages><issn>1932-2259</issn><eissn>1932-2267</eissn><abstract>Introduction
The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown.
Methods
Primary, incident cases of early stage prostate cancer (
n
= 473) were identified from the Buffalo VA Medical Center tumor registry and matched to body size, demographic, comorbidity, and treatment exposure data from veteran medical records. Multilevel modeling was used to assess the association between ADT and changes in BMI.
Results
On average, survivors were overweight at diagnosis and showed small, non-significant changes in BMI over time. However, among those survivors with a history of ADT, a significant decrease of 0.05 BMI units per year was associated with each additional dose of ADT (
p
< 0.001). When the association between BMI rate of change and ADT was allowed to vary with respect to age, additional doses of ADT predicted stronger decreases in BMI for younger survivors as compared to older survivors (
p
< 0.05). Neither a history of surgery nor radiation influenced the association between ADT use and BMI.
Conclusions
Declines in BMI in relation to ADT exposure may be reflective of unfavorable changes in body composition, especially decreased muscle mass, that is most pronounced in younger survivors.
Implications for Cancer Survivors
Survivors on ADT may benefit from close monitoring of physical functioning and referral for exercise interventions to preserve muscle mass and improve health related quality of life.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>19760149</pmid><doi>10.1007/s11764-009-0099-9</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-2259 |
| ispartof | Journal of cancer survivorship, 2009-12, Vol.3 (4), p.233-240 |
| issn | 1932-2259 1932-2267 |
| language | eng |
| recordid | cdi_proquest_journals_89190876 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Androgen Antagonists - therapeutic use Androgens Body Mass Index Drug therapy Health Informatics Health Promotion and Disease Prevention Humans Longitudinal Studies Male Medicine Medicine & Public Health Oncology Primary Care Medicine Prognosis Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Public Health Quality of Life Research Survivor Survivors Treatment Outcome |
| title | Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A21%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20assessment%20of%20BMI%20in%20relation%20to%20ADT%20use%20among%20early%20stage%20prostate%20cancer%20survivors&rft.jtitle=Journal%20of%20cancer%20survivorship&rft.au=Beehler,%20Gregory%20P.&rft.date=2009-12-01&rft.volume=3&rft.issue=4&rft.spage=233&rft.epage=240&rft.pages=233-240&rft.issn=1932-2259&rft.eissn=1932-2267&rft_id=info:doi/10.1007/s11764-009-0099-9&rft_dat=%3Cproquest_cross%3E1897946901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=89190876&rft_id=info:pmid/19760149&rfr_iscdi=true |